{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:22:15Z","timestamp":1794007335380,"version":"4.8.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Mycology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.mycmed.2025.101534","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T02:38:59Z","timestamp":1737081539000},"page":"101534","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Ibrexafungerp for the treatment of vulvovaginal candidiasis: A systematic review and meta-analysis of randomized placebo-controlled trials"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8186-2926","authenticated-orcid":false,"given":"Chia Siang","family":"Kow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5390-7026","authenticated-orcid":false,"given":"Dinesh Sangarran","family":"Ramachandram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4058-2215","authenticated-orcid":false,"given":"Syed Shahzad","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3754-1690","authenticated-orcid":false,"given":"Kaeshaelya","family":"Thiruchelvam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mycmed.2025.101534_bib0001","unstructured":"Centers for Disease Control and Prevention. Vulvovaginal candidiasis (VVC)- sexually transmitted infections treatment guidelines, 2021. Available from: https:\/\/www.cdc.gov\/std\/treatment-guidelines\/candidiasis.htm#:\u223c:text=Vulvovaginal%20Candidiasis%20(VVC)&text=VVC%20usually%20is%20caused%20by,dysuria%2C%20and%20abnormal%20vaginal%20discharge"},{"issue":"2","key":"10.1016\/j.mycmed.2025.101534_bib0002","first-page":"328","article-title":"Chronic vulvar pain and health-related quality of life in women with vulvodynia","volume":"13","author":"Patla","year":"2023","journal-title":"Life (Basel)"},{"issue":"4","key":"10.1016\/j.mycmed.2025.101534_bib0003","first-page":"913","article-title":"Drug resistance and biofilm formation in candida species of vaginal origin","volume":"51","author":"Alikhani","year":"2022","journal-title":"Iran J Public Health"},{"key":"10.1016\/j.mycmed.2025.101534_bib0004","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1128\/AAC.46.9.3001-3012.2002","article-title":"The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro","volume":"46","author":"Bowman","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2025.101534_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.642358","article-title":"Ibrexafungerp, a novel oral triterpenoid antifungal in development: overview of antifungal activity against candida glabrata","volume":"11","author":"Gamal","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.mycmed.2025.101534_bib0006","unstructured":"Cochrane Methods Bias. RoB 2: a revised Cochrane risk-of-bias tool for randomized trials. 2023. Available from: https:\/\/methods.cochrane.org\/bias\/resources\/rob-2-revised-cochrane-risk-bias-tool-randomized-trials"},{"key":"10.1016\/j.mycmed.2025.101534_bib0007","doi-asserted-by":"crossref","DOI":"10.1007\/s15010-024-02233-w","article-title":"Efficacy and safety of oral ibrexafungerp in Chinese patients with vulvovaginal candidiasis: a phase III, randomized, double-blind study","author":"Wang","year":"2024","journal-title":"Infection"},{"issue":"3","key":"10.1016\/j.mycmed.2025.101534_bib0008","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/1471-0528.16972","article-title":"Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a\u2009global phase 3, randomised, placebo-controlled superiority study (VANISH 306)","volume":"129","author":"Sobel","year":"2022","journal-title":"BJOG"},{"issue":"11","key":"10.1016\/j.mycmed.2025.101534_bib0009","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/cid\/ciab750","article-title":"Ibrexafungerp versus placebo for vulvovaginal candidiasis treatment: a phase 3, randomized, controlled superiority trial (VANISH 303)","volume":"74","author":"Schwebke","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mycmed.2025.101534_bib0010","article-title":"Phase 3 study of oral ibrexafungerp (SCY-078) Vs. Placebo in subjects with recurrent vulvovaginal candidiasis (VVC) (CANDLE). Clinicaltrials.gov identifier: NCT04029116","author":"Azie","year":"2023","journal-title":"Updated"},{"issue":"3","key":"10.1016\/j.mycmed.2025.101534_bib0011","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1128\/AAC.47.3.956-964.2003","article-title":"Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei","volume":"47","author":"Onyewu","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.mycmed.2025.101534_bib0012","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/cid\/ciab841","article-title":"Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis","volume":"74","author":"Nyirjesy","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.mycmed.2025.101534_bib0013","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3390\/jof7030163","article-title":"Ibrexafungerp: a first-in-class oral triterpenoid glucan synthase inhibitor","volume":"7","author":"Jallow","year":"2021","journal-title":"J Fungi"},{"issue":"15","key":"10.1016\/j.mycmed.2025.101534_bib0014","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","article-title":"The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin","volume":"81","author":"Hoenigl","year":"2021","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.mycmed.2025.101534_bib0015","doi-asserted-by":"crossref","first-page":"e28776","DOI":"10.1016\/j.heliyon.2024.e28776","article-title":"Efficacy and safety of ibrexafungerp in the treatment of vulvovaginal candidiasis: a meta-analysis of randomized controlled trials","volume":"10","author":"He","year":"2024","journal-title":"Heliyon"},{"issue":"2","key":"10.1016\/j.mycmed.2025.101534_bib0016","doi-asserted-by":"crossref","first-page":"S771","DOI":"10.1016\/j.ajog.2022.11.106","article-title":"A phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of once monthly oral ibrexafungerp for prevention of recurrent vulvovaginal candidiasis (VVC)","volume":"228","author":"Goje","year":"2023","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.mycmed.2025.101534_bib0017","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.3389\/fmicb.2019.02573","article-title":"Fungal cell wall: emerging antifungals and drug resistance","volume":"10","author":"Lima","year":"2019","journal-title":"Front Microbiol"},{"issue":"3","key":"10.1016\/j.mycmed.2025.101534_bib0018","first-page":"324","article-title":"Ibrexafungerp (brexafemme) for the treatment of vulvovaginal candidiasis","volume":"106","author":"Woolfolk","year":"2022","journal-title":"Am Fam Physician"},{"issue":"12","key":"10.1016\/j.mycmed.2025.101534_bib0019","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01075-23","article-title":"Safety, tolerability, and pharmacokinetics of ibrexafungerp in healthy Chinese subjects: a randomized, double-blind, placebo-controlled phase 1 trial","volume":"67","author":"Liu","year":"2023","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Medical Mycology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1156523325000034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1156523325000034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T23:57:10Z","timestamp":1742255830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1156523325000034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1156523325000034"],"URL":"https:\/\/doi.org\/10.1016\/j.mycmed.2025.101534","relation":{},"ISSN":["1156-5233"],"issn-type":[{"value":"1156-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ibrexafungerp for the treatment of vulvovaginal candidiasis: A systematic review and meta-analysis of randomized placebo-controlled trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Medical Mycology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mycmed.2025.101534","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 SFMM. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101534"}}